Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience

Lignende værker

• Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience
  af: Fujii, Takeo, et al.
  Udgivet: (2017)
• Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer
  af: Subudhi, Sumit K, et al.
  Udgivet: (2015)
• Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project
  af: Edwards, Beatrice J., et al.
  Udgivet: (2017)
• Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
  af: Bilen, Mehmet Asim, et al.
  Udgivet: (2016)
• Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
  af: Subudhi, Sumit K., et al.
  Udgivet: (2016)